Business Combination, Contingent Consideration, Royalty Payment Period

No definition available.

Name:	prgo_BusinessCombinationContingentConsiderationRoyaltyPaymentPeriod
Namespace Prefix:	prgo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Business Combination, Number Of Products Purchased

+ References

No definition available.

+ Details

Name:	prgo_BusinessCombinationNumberOfProductsPurchased
Namespace Prefix:	prgo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent Proceeds from Divestiture of Business, Milestone One, Maximum

+ References

No definition available.

+ Details

Name:	prgo_ContingentProceedsfromDivestitureofBusinessMilestoneOneMaximum
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contingent Proceeds from Divestiture of Business, Milestone Two, Maximum

+ References

No definition available.

+ Details

Name:	prgo_ContingentProceedsfromDivestitureofBusinessMilestoneTwoMaximum
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e845-128460

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e848-128460

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain (loss) from sale or disposal of an organization or integrated set of activities (for example, but not limited to, a partnership or corporation) engaged in providing a product or service in a commercial, industrial, or professional environment.

+ References

No definition available.

+ Details

Name:	us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2611-110228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_BenzaclinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_TretinoinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_DevelopmentstagerxproductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	prgo_ResearchanddevelopmentcontractualarrangementAxis=prgo_ContractualarrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_ConsumerHealthcareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_SpecialtySciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_ANDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=prgo_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions and Divestitures (Details) $ in Millions									3 Months Ended		9 Months Ended	12 Months Ended
Acquisitions and Divestitures (Details) $ in Millions	Mar. 27, 2017 USD ($)	Feb. 01, 2017 USD ($)	Jan. 03, 2017 USD ($)	Aug. 05, 2016 USD ($)	Aug. 02, 2016 USD ($)	Mar. 01, 2016 USD ($)	Jan. 22, 2016 USD ($)	May 01, 2015 USD ($)	Apr. 01, 2017 USD ($)	Apr. 02, 2016 USD ($)	Oct. 01, 2016	Dec. 31, 2016 USD ($) products
Business Acquisition [Line Items]
Useful life of intangible asset											20 years
Research and development									$ 39.8	$ 45.3
Proceeds from sale of business and other assets		$ 7.7							$ 25.3	$ 0.0
Benzaclin
Business Acquisition [Line Items]
Effective date of acquisition					Aug. 02, 2016
Percentage of interests acquired					60.90%
Purchase price paid					$ 62.0
Tretinoin
Business Acquisition [Line Items]
Effective date of acquisition							Jan. 22, 2016
Purchase price paid							$ 416.4
Contingent consideration							$ 0.0
Development stage rx products
Business Acquisition [Line Items]
Effective date of acquisition						Mar. 01, 2016
Purchase price paid						$ 0.0
Contingent consideration						$ 24.9
All Other
Business Acquisition [Line Items]
Purchase price paid												$ 17.1
Contingent consideration												$ 26.2
Number of products acquired \| products												4
Developed technology rights \| Tretinoin
Business Acquisition [Line Items]
Useful life of intangible asset							20 years
Non-compete agreements \| Tretinoin
Business Acquisition [Line Items]
Useful life of intangible asset							5 years
Licensing Agreements \| Benzaclin
Business Acquisition [Line Items]
Useful life of intangible asset					9 years
Minimum \| Development stage rx products
Business Acquisition [Line Items]
Royalty payment period						7 years
Maximum \| Development stage rx products
Business Acquisition [Line Items]
Royalty payment period						10 years
Contractual Arrangement
Business Acquisition [Line Items]
Research and development								$ 18.0
CHCA
Business Acquisition [Line Items]
Proceeds from sale of business and other assets				$ 61.8
Impairment charge												$ 6.2
Specialty Sciences
Business Acquisition [Line Items]
Gain on sale of unit	$ 17.1
ANDA
Business Acquisition [Line Items]
Proceeds from sale of business and other assets			$ 15.0
Royalty Pharma
Business Acquisition [Line Items]
Proceeds from sale of business and other assets	2,200.0
Proceeds from sale of business, maximum milestone payments in year two	250.0
Proceeds from sale of business, maximum milestone payments in year four	$ 400.0